Hualan Biological Engineering, Inc. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

762.11

1,216.13

1,580.69

930.59

859.23

888.55

1,837.94

Other Operating Income

0.00

Total Operating income

762.11

1,216.13

1,580.69

930.59

859.23

888.55

1,837.94

Raw Material Cost

379.63

549.66

605.20

501.42

407.33

380.25

545.93

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

0.10

3.86

0.89

2.76

2.74

1.57

3.17

Selling and Distribution Expenses

52.68

253.26

545.22

158.77

49.11

193.73

598.20

Other Expenses

5.94

8.88

6.23

8.15

5.30

10.77

5.21

Total Expenditure (Excl Depreciation)

491.81

895.61

1,213.57

744.40

512.22

683.28

1,199.42

Operating Profit (PBDIT) excl Other Income

270.3

320.5

367.1

186.20000000000002

347

205.3

638.5

Other Income

20.74

28.83

26.17

35.15

33.80

16.97

43.26

Operating Profit (PBDIT)

278.27

337.71

452.84

292.61

451.90

207.34

739.90

Interest

0.10

3.86

0.89

2.76

2.74

1.57

3.17

Exceptional Items

4.07

-2.17

4.83

7.05

5.45

9.31

4.27

Gross Profit (PBDT)

382.49

666.47

975.49

429.16

451.89

508.30

1,292.01

Depreciation

0.00

70.74

70.04

69.20

Profit Before Tax

282.24

260.95

386.04

226.87

384.57

145.89

671.80

Tax

46.91

28.64

55.96

28.01

60.74

-4.46

102.46

Provisions and contingencies

0.00

Profit After Tax

230.35

155.98

268.56

202.72

313.14

164.19

483.46

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

230.35

155.98

268.56

202.72

313.14

164.19

483.46

Share in Profit of Associates

0.00

Minority Interest

12.25

16.31

36.45

-3.86

10.70

-19.88

78.92

Other related items

0.00

Consolidated Net Profit

242.59

172.29

305.01

198.86

323.83

144.31

562.38

Equity Capital

0.00

Face Value

1.0

0.0

1.0

Reserves

11,720.32

11,500.61

11,371.87

12,013.17

12,172.14

11,858.78

11,697.01

Earnings per share (EPS)

0.13

0.09

0.15

0.11

0.17

0.09

0.26

Diluted Earnings per share

0.13

0.09

0.15

0.11

0.17

0.09

0.26

Operating Profit Margin (Excl OI)

33.79%

19.58%

22.52%

20.14%

40.51%

13.64%

34.14%

Gross Profit Margin

37.03%

27.27%

28.9%

31.91%

52.91%

24.21%

40.32%

PAT Margin

30.23%

12.83%

16.99%

21.78%

36.44%

18.48%

26.3%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is -37.33% vs -23.07% in Dec 2025

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 40.80% vs -43.51% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is -16.64% vs -27.61% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is -97.44% vs 333.33% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Hualan Biological Engineering, Inc. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

762.11

Other Operating Income

0.00

Total Operating income

762.11

Raw Material Cost

379.63

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

0.10

Selling and Distribution Expenses

52.68

Other Expenses

5.94

0.00

5.94

Total Expenditure (Excl Depreciation)

491.81

Operating Profit (PBDIT) excl Other Income

270.30

0.00

270.30

Other Income

20.74

Operating Profit (PBDIT)

278.27

Interest

0.10

Exceptional Items

4.07

Gross Profit (PBDT)

382.49

Depreciation

0.00

Profit Before Tax

282.24

Tax

46.91

Provisions and contingencies

0.00

Profit After Tax

230.35

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

230.35

Share in Profit of Associates

0.00

Minority Interest

12.25

Other related items

0.00

Consolidated Net Profit

242.59

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

11,720.32

Earnings per share (EPS)

0.13

Diluted Earnings per share

0.13

Operating Profit Margin (Excl OI)

33.79%

0.00

33.79%

Gross Profit Margin

37.03%

0.00

37.03%

PAT Margin

30.23%

0.00

30.23%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 76.21 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -37.33% vs -23.07% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -11.30% vs 9.13% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 24.26 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 40.80% vs -43.51% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -25.08% vs 18.00% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 25.75 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -16.64% vs -27.61% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -38.41% vs 22.75% in Mar 2025

Quarterly - Interest

Interest 0.01 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -97.44% vs 333.33% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -96.30% vs -40.00% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 33.79%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025